Intimation of Transcript of Q4 FY 26 for the Earnings Conference Call held on April 28, 2026.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Rossari Biotech delivered its highest-ever quarterly revenue (Rs. 684.9 crore) and EBITDA (Rs. 77.3 crore) in Q4 FY26, with full-year revenue of Rs. 2,396.4 crore growing 15% YoY. All three segments performed well—HPPC grew 18%, Textiles 20%, and AHN 14% in Q4. However, consolidated EBITDA margin compressed to 11.9% in FY26 from 12.7% due to raw material price hikes (25-30% in March) and losses in the institutional/B2C business. Management guided for at least 15% revenue growth in FY27 with EBITDA margins维持在 12%-13%, while planning Rs. 50-75 crore CAPEX (reduced from Rs. 192 crore) and targeting to become debt-free in 18 months. The company is divesting non-core consumer businesses and focusing on higher-margin pharma, agro, and oil & gas segments to improve profitability.
The company's diversified growth and margin recovery plans are positive, but investors should note the ongoing weakness in B2C/institutional businesses and compressed margins due to raw material costs. The focus on higher-margin pharma and reduced CAPEX could improve return ratios going forward.